英夫利昔单抗与乌司奴单抗治疗中重度活动期克罗恩病的疗效及安全性对比研究  

Comparative study on the efficacy and safety of infliximab and ustekinumab in the treatment of moderate and severe active Crohn′s disease

作　　者：桂道军[1] 沈志刚 王龙 GUI Daojun;SHEN Zhigang;WANG Long(Department of Gastroenterology,Suzhou Yongding Hospital,Jiangsu Province,Suzhou 215200,China)

机构地区：[1]苏州永鼎医院消化内科,江苏省苏州市215200

出　　处：《临床合理用药》2024年第36期33-36,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的比较英夫利昔单抗与乌司奴单抗治疗中重度活动期克罗恩病的疗效及安全性。方法选取2022年1月—2024年1月苏州永鼎医院收治的100例中重度活动期克罗恩病患者作为研究对象,采用随机数字表法分为乌司奴单抗组和英夫利昔单抗组,各50例。乌司奴单抗组给予乌司奴单抗注射液治疗,英夫利昔单抗组给予注射用英夫利昔单抗治疗,2组患者均持续治疗6个月。比较2组克罗恩病活动指数(CDAI)评分、治疗应答率、临床缓解率、炎性指标[血清C反应蛋白(CRP)、红细胞沉降率(ESR)]及不良事件。结果治疗6个月后,2组CDAI评分降低,且英夫利昔单抗组低于乌司奴单抗组(P<0.05或P<0.01);2组治疗应答率比较差异无统计学意义(P>0.05);但英夫利昔单抗组临床缓解率高于乌司奴单抗组(P<0.05);2组血清CPR水平及ESR降低,且英夫利昔单抗组低于乌司奴单抗组(P<0.01)。英夫利昔单抗组与乌司奴单抗组药物不良事件总发生率比较差异无统计学意义(12.00%vs.10.00%,χ^(2)=0.102,P=0.749)。结论与乌司奴单抗相比,英夫利昔单抗治疗中重度活动期克罗恩病具有较高的临床缓解率,可更有效地减轻机体炎性反应及病情程度,但在临床用药时应警惕机会性感染及急性/重度输注反应等不良事件发生。Objective To compare the efficacy and safety of infliximab and ustekinumab in the treatment of moderate and severe active Crohn′s disease.Methods A total of 100 patients with moderate and severe active Crohn′s disease admitted to Suzhou Yongding Hospital from January 2022 to January 2024 were selected,and they were divided into the ustekinumab group and the infliximab group,with 50 patients in each group.Patients in the ustekinumab group were treated with ustekinumab injection,and patients in the infliximab group were treated with infliximab for injection,both groups were treated for 6 months.CDAI score,treatment response rate,clinical remission rate,inflammatory indexes(CRP,ESR)and incidence of adverse events were compared between the two groups.Results After 6 months of treatment,CDAI score in the two groups was lower than that before treatment,and the infliximab group was lower than that of the ustekinumab group(P<0.05 or P<0.01);There was no significant difference of treatment response rate between the two groups(P>0.05);Clinical remission rate in the infliximab group was higher than that of the ustekinumab group(P<0.05);Serum level of CPR and ESR of the two groups were lower than those before treatment,and the infliximab group were lower than those of the ustekinumab group(P<0.01).There was no significant difference of incidence of adverse events between the infliximab group and the ustekinumab group(12.00%vs.10.00%,χ^(2)=0.102,P=0.749).Conclusion Compared with ustekinumab,infliximab has a higher clinical remission rate in the treatment of moderate and severe active Crohn′s disease,which can more effectively reduce the body′s inflammatory response and the severity of the disease.However,we should be vigilant about the occurrence of adverse events such as opportunistic infections and acute/severe infusion reactions during clinical medication.

关 键 词：克罗恩病 英夫利昔单抗 乌司奴单抗 疗效比较 安全性 

分 类 号：R574[医药卫生—消化系统]